Not Yet RecruitingNot Applicable

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

United States200 participantsStarted 2026-09-01

Plain-language summary

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age more than or equal to 18 years * Consenting to collection of genetic material and willing to adhere to study protocol * Stage I/II Hypertension (Systolic blood pressure: 130-159 and Diastolic blood pressure: 80-99 mm Hg) Exclusion Criteria: * Body mass index (BMI) more than 45 kg/m2 * History of uncontrolled hypertension (i.e., Systolic blood pressure more than or equal to 160 mmHg and/or Diastolic blood pressure more than or equal to 100 mmHg) * If taking more than or equal to 2 blood pressure medications at the time of screening * Systolic blood pressure more than 180 and/or Diastolic blood pressure more than or equal to 120 mmHg at any point in the study * Present or past history of major cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, heart failure, stroke, transient ischemic attack, or seizure. * Pregnant or breastfeeding individuals * History of kidney disease * History of insulin requiring diabetes * Estimated glomerular filtration rate less than 60ml/min/1.73 m2, albumin creatinine ratio more than or equal to 30 mg/g * Hepatic transaminase levels more than 3 times the upper limit of normal * Anemia (men, Hb less than 13 g/dL; women, Hb less than 12 g/dL)

What they're measuring

Change in 24h mean Systolic Blood Pressure (SBP)

Timeframe: 3 weeks

Change in N-terminal pro-B-type Natriuretic Peptide (NTproBNP) (NTproBNP)

Timeframe: 3 weeks

Trial details

NCT IDNCT07118592

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-06-01

Contact for this trial

Nehal Vekariya, MS

2059347173 nvekariya@uabmc.edu